That may sound small, but in an industry where growth is measured in tenths of a percent, its enough to make a difference
Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates, Mikael Dolsten, MD, the chief scientific officer and president of research and development at Pfizer, said in a statement about the new drug
GLP-1 Drugs Can Lower Healthcare Costs to Society GLP-1 drugs have been touted as groundbreaking biotech innovations on several fronts
Here's what most programs get wrong: they focus on what you can't eat instead of strategically choosing foods that enhance your treatment
Cardiovascular diseases (CVDs) are the leading cause of mortality post-transplant, driven by prevalent traditional risk factors, along with complications related to chronic kidney disease (CKD), such as left ventricular hypertrophy and mineral bone disease, which often persist after the transplant [3, 4]